Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Telomerase and pluripotency factors jointly regulate stemness in pancreatic cancer stem cells

  • Walter, Karolin
  • Rodriguez-Aznar, Eva
  • Ventura Ferreira, Monica S.
  • Frappart, Pierre-Olivier
  • Dittrich, Tabea
  • Tiwary, Kanishka
  • Meessen, Sabine
  • Lerma, L.
  • Daiss, Nora
  • Schulte, Lucas-Alexander
  • Najafova, Zeynab
  • Arnold, Frank
  • Usachov, Valentyn
  • Azoitei, Ninel
  • Erkan, Mert M.
  • Lechel, André
  • Brümmendorf, Tim H.
  • Seufferlein, Thomas
  • Kleger, Alexander
  • Tabarés, E.
© 2021 by the authors., To assess the role of telomerase activity and telomere length in pancreatic CSCs we used different CSC enrichment methods (CD133, ALDH, sphere formation) in primary patient-derived pancreatic cancer cells. We show that CSCs have higher telomerase activity and longer telomeres than bulk tumor cells. Inhibition of telomerase activity, using genetic knockdown or pharmacological inhibitor (BIBR1532), resulted in CSC marker depletion, abrogation of sphere formation in vitro and reduced tumorigenicity in vivo. Furthermore, we identify a positive feedback loop between stemness factors (NANOG, OCT3/4, SOX2, KLF4) and telomerase, which is essential for the self-renewal of CSCs. Disruption of the balance between telomerase activity and stemness factors eliminates CSCs via induction of DNA damage and apoptosis in primary patient-derived pancreatic cancer samples, opening future perspectives to avoid CSC-driven tumor relapse. In the present study, we demonstrate that telomerase regulation is critical for the “stemness” maintenance in pancreatic CSCs and examine the effects of telomerase inhibition as a potential treatment option of pancreatic cancer. This may significantly promote our understanding of PDAC tumor biology and may result in improved treatment for pancreatic cancer patients., This research was funded by a Max Eder Fellowship of the German Cancer Aid (111746), a German Cancer Aid Priority Program ‘Translational Oncology’ 70112505, by a Collaborative Research Centre grant (316249678—SFB 1279) of the German Research Foundation, and by a Hector Foundation Cancer Research grant (M65.1) to P.C.H., B.S.J. is supported by a Rámon y Cajal Merit Award (RYC2012-12104) from the Ministerio de Economía y Competitividad, Spain and a Coordinated grant (GC16173694BARB) from the Fundación Asociación Española Contra el Cáncer (AECC). K.W. is supported by a Baustein 3.2 by Ulm University.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma

  • Alonso-Nocelo, Marta
  • Ruiz-Cañas, Laura
  • Sancho, Patricia
  • Alcalá, Sonia
  • Pedrero García, Coral
  • Vallespinós, Mireia
  • López-Gil, Juan Carlos
  • Ochando, Marina
  • García-García, Elena
  • Trabulo, Sara María David
  • Martinelli, Paola
  • Sánchez-Tomero, Patricia
  • Sánchez-Palomo, Carmen
  • González-Santamaría, Patricia
  • Yuste Pérez, Lourdes
  • Wörmann, Sonja M.
  • Kabacaoglu, Derya
  • Earl, Julie
  • Martín, Alberto
  • Salvador, Fernando
  • Valle, Sandra
  • Martin-Hijano, Laura
  • Carrato, Alfredo
  • Erkan, Mert M.
  • García-Bermejo, María Laura
  • Hermann, Patrick C.
  • Algül, Hana
  • Moreno-Bueno, Gema
  • Heeschen, Christopher
  • Portillo, Francisco
  • Cano, Amparo
  • Sainz, Bruno Jr.
[Objective]: The lysyl oxidase-like protein 2 (LOXL2) contributes to tumour progression and metastasis in different tumour entities, but its role in pancreatic ductal adenocarcinoma (PDAC) has not been evaluated in immunocompetent in vivo PDAC models., [Design]: Towards this end, we used PDAC patient data sets, patient-derived xenograft in vivo and in vitro models, and four conditional genetically-engineered mouse models (GEMMS) to dissect the role of LOXL2 in PDAC. For GEMM-based studies, K-Ras +/LSL-G12D;Trp53 LSL-R172H;Pdx1-Cre mice (KPC) and the K-Ras +/LSL-G12D;Pdx1-Cre mice (KC) were crossed with Loxl2 allele floxed mice (Loxl2Exon2 fl/fl) or conditional Loxl2 overexpressing mice (R26Loxl2 KI/KI) to generate KPCL2KO or KCL2KO and KPCL2KI or KCL2KI mice, which were used to study overall survival; tumour incidence, burden and differentiation; metastases; epithelial to mesenchymal transition (EMT); stemness and extracellular collagen matrix (ECM) organisation., [Results]: Using these PDAC mouse models, we show that while Loxl2 ablation had little effect on primary tumour development and growth, its loss significantly decreased metastasis and increased overall survival. We attribute this effect to non-cell autonomous factors, primarily ECM remodelling. Loxl2 overexpression, on the other hand, promoted primary and metastatic tumour growth and decreased overall survival, which could be linked to increased EMT and stemness. We also identified tumour-associated macrophage-secreted oncostatin M (OSM) as an inducer of LOXL2 expression, and show that targeting macrophages in vivo affects Osm and Loxl2 expression and collagen fibre alignment., [Conclusion]: Taken together, our findings establish novel pathophysiological roles and functions for LOXL2 in PDAC, which could be potentially exploited to treat metastatic disease., JCL-G received support from a 'la Caixa' Foundation (ID 100010434) fellowship (LCF/BQ/DR21/11880011). This study was supported by ISCIII FIS grants PI18/00757 and PI21/01110 (BSJ) and PI18/00267 (LG-B), and grants from the Spanish Ministry of Economy and Innovation SAF2016-76504-R (ACan and FP), PID2019-111052RB-I00 (FP), PID2019-104644RB-I00 (GM-B), a Ramón y Cajal Merit Award RYC-2012–12104 (BSJ) and ISCIII, CIBERONC, CB16/12/00446 (ACar) and CB16/12/00295 (ACan and GM-B), all of them co-financed through Fondo Europeo de Desarrollo Regional (FEDER) 'Una manera de hacer Europa'; a Fero Foundation Grant (BSJ); a Coordinated grant (GC16173694BARB) from the Fundación Científica Asociación Española Contra el Cáncer (FC-AECC) (BSJ); a Miguel Servet award (CP16/00121) (PS); a DFG, German Research Foundation Grant—Project no: 492 436 553 (KG); and a Max Eder Fellowship of the German Cancer Aid (111746) (PCH)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy

  • Alcalá, Sonia
  • Villarino, Lara
  • Ruiz-Cañas, Laura
  • Couceiro, José R.
  • Martínez‑Calvo, Miguel
  • Palencia-Campos, Adrián
  • Navarro, Diego
  • Cabezas-Sainz, Pablo
  • Rodríguez‑Arabaolaza, Iker
  • Cordero‑Barreal, Alfonso
  • Trilla-Fuertes, Lucía
  • Rubiolo, Juan A.
  • Batres-Ramos, Sandra
  • Vallespinós, Mireia
  • González‑Páramos, Cristina
  • Rodríguez, Jéssica
  • Gámez, Ángelo
  • Fresno Vara, Juan Ángel
  • Fra Fernández, Sara
  • Benito Berlinches, Amparo
  • Moreno‑Mata, Nicolás
  • Torres Redondo, Ana María
  • Carrato, Alfredo
  • Hermann, Patrick C.
  • Sánchez, Laura
  • Torrente, Susana
  • Fernández‑Moreno, Miguel Ángel
  • Mascareñas, José L.
  • Sainz, Bruno Jr.
[Background]: Previous studies by our group have shown that oxidative phosphorylation (OXPHOS) is the main pathway by which pancreatic cancer stem cells (CSCs) meet their energetic requirements; therefore, OXPHOS represents an Achille’s heel of these highly tumorigenic cells. Unfortunately, therapies that target OXPHOS in CSCs are lacking., [Methods]: The safety and anti-CSC activity of a ruthenium complex featuring bipyridine and terpyridine ligands and one coordination labile position (Ru1) were evaluated across primary pancreatic cancer cultures and in vivo, using 8 patient-derived xenografts (PDXs). RNAseq analysis followed by mitochondria-specific molecular assays were used to determine the mechanism of action., [Results]: We show that Ru1 is capable of inhibiting CSC OXPHOS function in vitro, and more importantly, it presents excellent anti-cancer activity, with low toxicity, across a large panel of human pancreatic PDXs, as well as in colorectal cancer and osteosarcoma PDXs. Mechanistic studies suggest that this activity stems from Ru1 binding to the D-loop region of the mitochondrial DNA of CSCs, inhibiting OXPHOS complex-associated transcription, leading to reduced mitochondrial oxygen consumption, membrane potential, and ATP production, all of which are necessary for CSCs, which heavily depend on mitochondrial respiration., [Conclusions]: Overall, the coordination complex Ru1 represents not only an exciting new anti-cancer agent, but also a molecular tool to dissect the role of OXPHOS in CSCs. Results indicating that the compound is safe, non-toxic and highly effective in vivo are extremely exciting, and have allowed us to uncover unprecedented mechanistic possibilities to fight different cancer types based on targeting CSC OXPHOS., This study was supported by a Fero Foundation Grant (B.S.,Jr.); Rámon y Cajal Merit Award (RYC-2012-12104) from the Ministerio de Economía y Competitividad, Spain (B.S.,Jr.); funding from the Beca Carmen Delgado/Miguel Pérez-Mateo from AESPANC-ACANPAN Spain (B.S.,Jr.); a Conquer Cancer Now Grant from the Concern Foundation (Los Angeles, CA, USA) (B.S.,Jr.); a Coordinated grant (GC16173694BARB; B.S.,Jr.) and SEED grant (IDEAS222917FERN; M.A.F.-M.) from the Fundación Asociación Española Contra el Cáncer (AECC); FIS grants PI18/00757 and PI21/01110 (B.S.,Jr.) and PT20/00045 (A.M.T.R and B.S.,Jr.), (co-financed through Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa”); an IGNICIA proof of concept grant (IN855A-2018/16) “RuCSC - targeting cancer stem cells using ruthenium compounds”, an initiative of the Agencia Gallega de Innovación (GAIN) to facilitate the access of I+D+i projects to the market (J.L.M and B.S.,Jr.), a La Caixa Research Consolidate grant (CC21-20122; J.L.M and B.S.,Jr.); Spanish national grants PID2019-110320RB-I00 (M.A.F.-M.) from the Ministerio de Ciencia e Innovación (MCIN), IJC2019-040358-I funded by MCIN/AEI/10.13039/501100011033 (J.R.), PID2019-108624RB-I00, PDC2021-121508-I00, PID2022-137318OB-I00 and ORFEO-CINQA network RED2018-102387-T (J.L.M.), the Consellería de Cultura, Educación e Ordenación Universitaria 2015-CP082, IN855A 2018/16, ED431C-2021/25 and Centro Singular de Investigación de Galicia accreditation 2019-2022: ED431G 2019/03 (J.L.M.), the European Union (European Regional Development Fund-ERDF corresponding to the multiannual financial framework 2014-2020), and the European Research Council Advanced Grant No. 340055, Proof-of-concept Grant No. 899334 (J.L.M.). a Max Eder Fellowship of the German Cancer Aid (111746) (P.C.H.); the German Research Foundation (DFG, CRC 1279 “Exploiting the human peptidome for Novel Antimicrobial and Anticancer Agents”) (P.C.H.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells

  • López-Gil, Juan Carlos
  • García-Silva, Susana
  • Ruiz-Cañas, Laura
  • Navarro, Diego
  • Palencia-Campos, Adrián
  • Giráldez-Trujillo, Antonio
  • Earl, Julie
  • Dorado, Jorge
  • Gómez-López, Gonzalo
  • Monfort-Vengut, Ana
  • Alcalá, Sonia
  • Gaida, Matthias M.
  • García-Mulero, Sandra
  • Cabezas-Sainz, Pablo
  • Batres-Ramos, Sandra
  • Barreto, Emma
  • Sánchez-Tomero, Patricia
  • Vallespinós, Mireia
  • Ambler, Leah
  • Lin, Meng-Lay
  • Aicher, Alexandra
  • García García de Paredes, Ana
  • Pinta, Carolina De La
  • Sanjuanbenito, Alfonso
  • Ruz-Caracuel, Ignacio
  • Rodríguez-Garrote, Mercedes
  • Guerra, Carmen
  • Carrato, Alfredo
  • Cárcer, Guillermo de
  • Sánchez, Laura
  • Nombela-Arrieta, César
  • Espinet, Elisa
  • Sánchez-Arévalo Lobo, Víctor J.
  • Heeschen, Christopher
  • Sainz, Bruno Jr.
[Objective]: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant ‘stem-like’ cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness. Thus, comprehending how this subset of cells evades the immune system is crucial for advancing novel therapies., [Design]: We used the KPC mouse model (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) and primary tumour cell lines to investigate putative CSC populations. Transcriptomic analyses were conducted to pinpoint new genes involved in immune evasion. Overexpressing and knockout cell lines were established with lentiviral vectors. Subsequent in vitro coculture assays, in vivo mouse and zebrafish tumorigenesis studies, and in silico database approaches were performed., [Results]: Using the KPC mouse model, we functionally confirmed a population of cells marked by EpCAM, Sca-1 and CD133 as authentic CSCs and investigated their transcriptional profile. Immune evasion signatures/genes, notably the gene peptidoglycan recognition protein 1 (PGLYRP1), were significantly overexpressed in these CSCs. Modulating PGLYRP1 impacted CSC immune evasion, affecting their resistance to macrophage-mediated and T-cell-mediated killing and their tumourigenesis in immunocompetent mice. Mechanistically, tumour necrosis factor alpha (TNFα)-regulated PGLYRP1 expression interferes with the immune tumour microenvironment (TME) landscape, promoting myeloid cell-derived immunosuppression and activated T-cell death. Importantly, these findings were not only replicated in human models, but clinically, secreted PGLYRP1 levels were significantly elevated in patients with PDAC., [Conclusions]: This study establishes PGLYRP1 as a novel CSC-associated marker crucial for immune evasion, particularly against macrophage phagocytosis and T-cell killing, presenting it as a promising target for PDAC immunotherapy., JCL-G received support from a ’la Caixa’ Foundation (ID 100010434) fellowship (LCF/BQ/DR21/11880011) and an EMBO Scientific Exchange Fellowship (ID 10210). AP-C was a recipient of a Juan de la Cierva Formación 2020 (FJC2020- 044220-I) grant. This study was supported by a Fero Foundation Grant (BSJr.) and Rámon y Cajal Merit Award (RYC-2012-12104) from the Ministerio de Economía y Competitividad, Spain (BSJr.); received funding from the Beca Carmen Delgado/ Miguel Pérez-Mateo from AESPANC-ACANPAN Spain (BSJr), a Conquer Cancer Now Grant from the Concern Foundation (Los Angeles, CA, USA) (BSJr), a Coordinated grant (GC16173694BARB) from the Fundación Asociación Española Contra el Cáncer (AECC) (BSJr; AC), and FIS grants PI18/00757 and PI21/01110 (BSJr), PI19/00514 (CG) and PI22/00492 (VJSAL); and cofinanced through Fondo Europeo de Desarrollo Regional ’Una manera de hacer Europa’). We also acknowledge the support from CIBERONC (CB16/12/00446) (AC) and Ayudas de Consolidación y Estructuración de grupos from Consellería de Educación, Universidade y Formación profesional (ED431C-2028/28) and Programa de axudas á etapa posdotoral, both from Xunta de Galicia (LS, PCS). Projects were financed via MCIN/ AEI/FEDER (10.13039/501100011033) (REF-PID2021-125705OB-I00 (GdC) and REF-RTI2018- 095496-B-100) (GdC), and PID2021-124520OA-I00 and RYC2020-029767 (EE), and others including AECC (LABAE16017DECÁ, GdC and TRNSC213893ESPI, SG-M); the Clinical Research Priority Program ’ImmunoCure’ of the University of Zurich (CN-A), the German Research Foundation (SFB1292 Project Number 318346496, TPQ1 and TP22), GA1818/2-3 (MMG) as well as funding from an ERC Advanced Investigator Grant (Pa-CSC 233460, CH), the European Community’s Seventh Framework Programme (FP7) under grant agreement n° 602783 (CAM-PaC, CH), the Fondazione del Piemonte per l’Oncologia – IRCCS (PTCRC-Intra-2021, CH), the Fondazione AIRC per la ricerca sul cancro (IG 2023 ID 28933, CH), the Shanghai Municipal Education Commission (2021-01-07-00-02-E00090, CH), and the National Science Foundation China (82130074, CH)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Autofluorescent Cancer Stem Cells: Potential Biomarker to Predict Recurrence in Resected Colorectal Tumors

  • Alcalá, Sonia
  • Serralta San Martín, Gonzalo
  • Muñoz-Fernández de Legaria, Marta
  • Moreno-Rubio, Juan
  • Salinas, Silvia
  • López-Gil, Juan Carlos
  • Rojo López, José Alberto
  • Martínez Alegre, Javier
  • Cortes Bandy, David Abraham
  • Zambrana, Francisco
  • Jiménez-Gordo, Ana María
  • Casado, Enrique
  • López-Gómez, Miriam
  • Sainz, Bruno Jr.
Cancer stem cells (CSC) in colorectal cancer drive intratumoral heterogeneity and distant metastases. Previous research from our group showed that CSCs can be easily detected by autofluorescence (AF). The aim of the present study was to evaluate the potential role of AF CSCs as a prognostic biomarker for colorectal cancer relapse. Seventy-five freshly resected tumors were analyzed by flow cytometry. AF was categorized as high (H-AF) or low, and the results were correlated with histologic features [grade of differentiation, presence of metastases in lymph nodes (LN), perivascular and lymphovascular invasion] and clinical variables (time to relapse and overall survival). Nineteen of the 75 (25.3%) patients experienced relapse (local or distant); of these 19 patients, 13 showed positive LNs and 6 had H-AF. Of note, four of them died before 5 years. Although patients with H-AF CSC percentages in the global population experienced 1.5 times increased relapse [HR, 1.47; 95% confidence interval (0.60–3.63)], patients with H-AF CSC percentages and LN metastases had the highest risk of relapse [HR, 7.92; P < 0.004; 95% confidence interval (1.97–31.82)]. These data support AF as an accurate and feasible marker to identify CSCs in resected colorectal cancer. A strong statistical association between H-AF CSCs and the risk of relapse was observed, particularly in patients with positive LNs, suggesting that H-AF patients might benefit from adjuvant chemotherapy regimens and intensive surveillance due to their high propensity to experience disease recurrence. Significance: AF has been proven to be an accurate biomarker for CSC identification; however, to date, their role as a prognostic factor after resection of colorectal cancer tumors has not been investigated. Our results show that determining the presence of AF CSCs after tumor resection has prognostic value and represents a potentially important tool for the management of patients with colorectal cancer., This study was supported by a Ramon ´ y Cajal Merit Award (RYC-2012-12104) from the Ministerio de Econom´ıa y Competitividad, Spain (B. Sainz); a Coordinated grant (GC16173694BARB) from the Fundacion ´ Asociacion ´ Española Contra el Cancer ´ (B. Sainz); FIS grants PI15/01507 and PI18/00757 (B. Sainz; cofinanced through Fondo Europeo de Desarrollo Regional “Una manera de hacer Europa”); and, in part, by the Programme S2018/BAA-4343 ALIBIRD2020-CM (E. Casado) “Precision nutrition therapeutic formulas for cancer” in the framework of the call for applications for technological aid 2018 for the implementation of R&D Programmes of the Community of Madrid, with 50% cofunding from the European Social Fund., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells

  • Valle, S.
  • Alcalá, S.
  • Martin-Hijano, L.
  • Cabezas-Sáinz, P.
  • Navarro, D.
  • Muñoz, E.R.
  • Yuste, L.
  • Tiwary, K.
  • Walter, K.
  • Ruiz-Cañas, L.
  • Alonso-Nocelo, M.
  • Rubiolo, J.A.
  • González-Arnay, E.
  • Heeschen, C.
  • Garcia-Bermejo, L.
  • Hermann, P.C.
  • Sánchez, L.
  • Sancho, P.
  • Fernández-Moreno, M.Á.
  • Sainz, B.
  • , Jr.
Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer death, has a 5-year survival rate of approximately 7–9%. The ineffectiveness of anti-PDAC therapies is believed to be due to the existence of a subpopulation of tumor cells known as cancer stem cells (CSCs), which are functionally plastic, and have exclusive tumorigenic, chemoresistant and metastatic capacities. Herein, we describe a 2D in vitro system for long-term enrichment of pancreatic CSCs that is amenable to biological and CSC-specific studies. By changing the carbon source from glucose to galactose in vitro, we force PDAC cells to utilize OXPHOS, resulting in enrichment of CSCs defined by increased CSC biomarker and pluripotency gene expression, greater tumorigenic potential, induced but reversible quiescence, increased OXPHOS activity, enhanced invasiveness, and upregulated immune evasion properties. This CSC enrichment method can facilitate the discovery of new CSC-specific hallmarks for future development into targets for PDAC-based therapies.